Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

INTRODUCTION: Osimertinib is an effective therapy in EGFR mutant NSCLC, but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of EGFR-mutant NSCLC. In hematologic malignancies, BCL-2 family inhibitors in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Bertino, Erin M., Gentzler, Ryan D., Clifford, Sarah, Kolesar, Jill, Muzikansky, Alona, Haura, Eric B., Piotrowska, Zofia, Camidge, D. Ross, Stinchcombe, Thomas E., Hann, Christine, Malhotra, Jyoti, Villaruz, Liza C., Paweletz, Cloud P., Lau, Christie L., Sholl, Lynette, Takebe, Naoko, Moscow, Jeffrey A., Shapiro, Geoffrey I., Jänne, Pasi A., Oxnard, Geoffrey R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7976451/
https://ncbi.nlm.nih.gov/pubmed/33376097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4084
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk